BELLUS Health Inc.
BLU
$0.01
Change (1 day)
$14.76
Year High
$6.38
Year Low
Categories
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Revenue of BELLUS Health Inc. (BLU)
Revenue in 2022 (TTM): $16 K
According to BELLUS Health Inc.'s latest financial reports the company's current revenue (TTM) is $16 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of BELLUS Health Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $16 K | $-3,514,736,653 | $-72,763,000 | $-76,020,000 | $-76,080,000 |
| 2021 | $16 K | $-2,221,947,831 | $-72,858,000 | $-71,423,000 | $-71,224,000 |
| 2020 | $15 K | $-1,430,417,932 | $-31,718,000 | $-31,757,000 | $-31,796,000 |
| 2019 | $26.79 K | $-994,486,698 | $-24,820,290 | $-26,385,051 | $-26,408,017 |
| 2018 | $25.7 K | $25.7 K | $-6,947,718 | $-6,669,457 | $-6,062,275 |
| 2017 | $131.21 K | $131.21 K | $-4,457,256 | $-1,441,750 | $-1,490,258 |
| 2016 | $1.41 M | $1.41 M | $-1,511,048 | $-1,646,455 | $-1,606,279 |
| 2015 | $2.9 M | $2.9 M | $28.1 K | $272.4 K | $145.57 K |
| 2014 | $2.05 M | $2.05 M | $-1,781,438 | $-1,737,505 | $-1,663,422 |
| 2013 | $2.12 M | $2.26 M | $-2,430,572 | $-911,934 | $-818,956 |
| 2012 | $2.31 M | $2.31 M | $-21,121,197 | $-13,238,443 | $-13,323,884 |
| 2011 | $3 M | $3 M | $-1,710,088 | $3.58 M | $3.35 M |
| 2010 | $2.41 M | $2.41 M | $-13,222,884 | $-19,734,842 | $-20,109,782 |
| 2009 | $-116,000 | $-116,000 | $-7,210,000 | $-8,227,000 | $-8,227,000 |
| 2008 | $584 K | $584 K | $-46,068,000 | $-48,223,000 | $-48,223,000 |
| 2007 | $1.51 M | $1.51 M | $-66,966,000 | $-81,073,000 | $-81,073,000 |
| 2006 | $2.74 M | $2.05 M | $-62,163,745 | $-64,676,361 | $-64,676,361 |
| 2005 | $2.91 M | $3.38 M | $-60,944,969 | $-62,309,759 | $-62,309,759 |
| 2004 | $109.8 K | $109.8 K | $-42,600,616 | $-43,587,775 | $-43,587,775 |
| 2003 | $ | $ | $-11,455,449 | $-13,300,121 | $-12,934,564 |
| 2001 | $2.25 M | $3.41 M | $-8,221,563 | $-8,732,608 | $-8,885,592 |
| 2000 | $5.52 M | $5.52 M | $-1,438,388 | $ | $-1,775,355 |
| 1999 | $118.83 K | $118.83 K | $-4,088,040 | $-3,995,544 | $-3,768,018 |